Capricor Therapeutics (CAPR) Change in Accured Expenses (2010 - 2026)

Capricor Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 334.27% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 51.28% decrease from a year earlier, with the FY2025 full-year figure at $6.0 million, up 208.27% from the prior year.
• Change in Accured Expenses retreated to -$3.1 million in Q1 2026 per CAPR's latest filing, from $2.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.2 million in Q4 2025 and bottomed at -$3.1 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $501815.0 (2023), against an average of $464028.2.
• Across the five-year window, Change in Accured Expenses surged 83134.6% in 2025 and tumbled 334.27% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $982327.0 in 2022, then tumbled by 155.15% to -$541709.0 in 2023, then soared by 406.44% to $1.7 million in 2024, then soared by 30.61% to $2.2 million in 2025, then plunged by 242.11% to -$3.1 million in 2026.
• Per Business Quant, the three latest CAPR Change in Accured Expenses figures stand at -$3.1 million (Q1 2026), $2.2 million (Q4 2025), and $971647.0 (Q3 2025).